Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Dermatology

Free Subscription Articles published in Lancet Retrieve available abstracts of 112 articles: HTML format

Single Articles

May 2024
1. COLES CE, Haviland JS, Kirby AM, Griffin C, et al
   Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial - Authors' reply.
   Lancet. 2024;403:1752.
   PubMed    
   
   
   
2. GREGUCCI F, Ciabattoni A
   Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
   Lancet. 2024;403:1751-1752.
   PubMed    
   
   
   
3. MULLIEZ T, De Ridder M
   Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
   Lancet. 2024;403:1751.
   PubMed    
   
   
   
4. GUINOT JL, Gutierrez C, Hannoun-Levi JM
   Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
   Lancet. 2024;403:1750-1751.
   PubMed    
   
   
   
5. MIZUMOTO M, Oshiro Y, Sakurai H
   Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
   Lancet. 2024;403:1749-1750.
   PubMed    
   
   
   
6. ZHAO D, Li Y, Qu Y, He C, et al
   Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
   Lancet. 2024;403:1749.
   PubMed    
   
   
   April 2024
7. DE SOUZA IC, Langer FW
   Post-radiation angiosarcoma of the breast in a patient with a history of invasive ductal carcinoma.
   Lancet. 2024;403:1681-1682.
   PubMed    
   
   
   
8. EARL HM
   Safe de-escalation of chemotherapy in HER2-positive early breast cancer.
   Lancet. 2024 Apr 3:S0140-6736(24)00535-X. doi: 10.1016/S0140-6736(24)00535.
   PubMed    
   
   
   
9. PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al
   3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
   Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054.
   PubMed     Abstract available
   
   
   March 2024
10. BRAYBROOKE J, Bradley R, Gray R, Hills R, et al
    Benefits and risks of anthracyclines in early-stage breast cancer - Authors' reply.
    Lancet. 2024;403:1240.
    PubMed    
    
    
    
11. KUDE DE ALMEIDA F, Soares Falcetta F, Dornelles Rosa D
    Benefits and risks of anthracyclines in early-stage breast cancer.
    Lancet. 2024;403:1239-1240.
    PubMed    
    
    
    
12. EMMI G, Bettiol A, Hatemi G, Prisco D, et al
    Behcet's syndrome.
    Lancet. 2024;403:1093-1108.
    PubMed     Abstract available
    
    
    
13. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
    Managing menopause after cancer.
    Lancet. 2024;403:984-996.
    PubMed     Abstract available
    
    
    February 2024
14. STONE GW, Christiansen EH, Ali ZA, Andreasen LN, et al
    Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.
    Lancet. 2024 Feb 21:S0140-6736(23)02454-6. doi: 10.1016/S0140-6736(23)02454.
    PubMed     Abstract available
    
    
    
15. KRONBICHLER A, Bajema IM, Bruchfeld A, Mastroianni Kirsztajn G, et al
    Diagnosis and management of ANCA-associated vasculitis.
    Lancet. 2024;403:683-698.
    PubMed     Abstract available
    
    
    
16. KIMBALL AB, Ravichandran S
    Secukinumab treatment of hidradenitis suppurativa: questions remain - Authors' reply.
    Lancet. 2024;403:617-618.
    PubMed    
    
    
    
17. ENDO M, Kami M
    Secukinumab treatment of hidradenitis suppurativa: questions remain.
    Lancet. 2024;403:617.
    PubMed    
    
    
    
18. MAUL JT, Kolios AGA, Thomsen SF, Ring HC, et al
    Secukinumab treatment of hidradenitis suppurativa: questions remain.
    Lancet. 2024;403:616-617.
    PubMed    
    
    
    January 2024
19. BAKKER T, Klopotowska JE, Dongelmans DA, Eslami S, et al
    The effect of computerised decision support alerts tailored to intensive care on the administration of high-risk drug combinations, and their monitoring: a cluster randomised stepped-wedge trial.
    Lancet. 2024 Jan 19:S0140-6736(23)02465-0. doi: 10.1016/S0140-6736(23)02465.
    PubMed     Abstract available
    
    
    
20. WEBER JS, Carlino MS, Khattak A, Meniawy T, et al
    Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
    Lancet. 2024 Jan 18:S0140-6736(23)02268-7. doi: 10.1016/S0140-6736(23)02268.
    PubMed     Abstract available
    
    
    
21. MAURER M, Ensina LF, Gimenez-Arnau AM, Sussman G, et al
    Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
    Lancet. 2024;403:147-159.
    PubMed     Abstract available
    
    
    
22. MOUSSA S, Netchiporouk E
    Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria.
    Lancet. 2024;403:118-119.
    PubMed    
    
    
    December 2023
23. TSAI CJ, Yang JT, Shaverdian N, Patel J, et al
    Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomi
    Lancet. 2023 Dec 14:S0140-6736(23)01857-3. doi: 10.1016/S0140-6736(23)01857.
    PubMed     Abstract available
    
    
    
24. BRAUNSTEIN LZ
    Optimising adjuvant breast radiotherapy via preoperative imaging.
    Lancet. 2023 Dec 5:S0140-6736(23)02698-3. doi: 10.1016/S0140-6736(23)02698.
    PubMed    
    
    
    
25. MANN GB, Skandarajah AR, Zdenkowski N, Hughes J, et al
    Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study.
    Lancet. 2023 Dec 5:S0140-6736(23)02476-5. doi: 10.1016/S0140-6736(23)02476.
    PubMed     Abstract available
    
    
    November 2023
26. SAKAI K, Miyamori D
    Hyperviscosity syndrome caused by cryoglobulinemia diagnosed by observing the reversible formation of gel upon cooling and warming the patient's serum.
    Lancet. 2023;402:1866.
    PubMed    
    
    
    
27. DEVJANI S, Engel PV, Javadi SS, Smith B, et al
    Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis.
    Lancet. 2023;402:1833-1834.
    PubMed    
    
    
    
28. GUTTMAN-YASSKY E, Simpson EL, Reich K, Kabashima K, et al
    Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply.
    Lancet. 2023;402:1834.
    PubMed    
    
    
    
29. 
    Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials.
    Lancet. 2023 Nov 3:S0140-6736(23)01082-6. doi: 10.1016/S0140-6736(23)01082.
    PubMed     Abstract available
    
    
    
30. LEVINE MN
    Effective and safe regional node irradiation in early breast cancer.
    Lancet. 2023 Nov 3:S0140-6736(23)01614-8. doi: 10.1016/S0140-6736(23)01614.
    PubMed    
    
    
    
31. ZAMAN M, de Vale ML, Coultas C, Goff L, et al
    Factors affecting the delivery of community-based salon interventions to prevent cardiovascular disease and breast cancer among ethnically diverse women in South London: a concept-mapping approach.
    Lancet. 2023;402 Suppl 1:S96.
    PubMed     Abstract available
    
    
    
32. SINGH M, Wambua S, Lee SI, Okoth K, et al
    Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
    Lancet. 2023;402 Suppl 1:S84.
    PubMed     Abstract available
    
    
    
33. HUNTLEY C, Torr B, Sud A, Houlston RS, et al
    The impact of risk stratification by polygenic risk and age on breast cancer screening in women aged 40-49 years: a modelling study.
    Lancet. 2023;402 Suppl 1:S54.
    PubMed     Abstract available
    
    
    
34. ACHARYA A, Darzi A, Judah G
    An SMS and animated video intervention to increase uptake of breast cancer screening: a randomised controlled trial.
    Lancet. 2023;402 Suppl 1:S17.
    PubMed     Abstract available
    
    
    October 2023
35. ESPIGOL-FRIGOLE G, Dejaco C, Mackie SL, Salvarani C, et al
    Polymyalgia rheumatica.
    Lancet. 2023;402:1459-1472.
    PubMed     Abstract available
    
    
    September 2023
36. HANOUNEH M, Arend LJ
    Ichthyosis in sarcoidosis: a rare skin manifestation of a systemic disease.
    Lancet. 2023;402:1083-1084.
    PubMed    
    
    
    
37. JO SJ, Jaihyun Cho R
    Preventing generalised pustular psoriasis.
    Lancet. 2023 Sep 19:S0140-6736(23)01480-0. doi: 10.1016/S0140-6736(23)01480.
    PubMed    
    
    
    
38. MORITA A, Strober B, Burden AD, Choon SE, et al
    Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
    Lancet. 2023 Sep 19:S0140-6736(23)01378-8. doi: 10.1016/S0140-6736(23)01378.
    PubMed     Abstract available
    
    
    
39. BECKER JC, Ugurel S, Leiter U, Meier F, et al
    Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
    Lancet. 2023;402:798-808.
    PubMed     Abstract available
    
    
    
40. SAIAG P, Blom A
    Should adjuvant nivolumab be used in surgically resected Merkel cell carcinoma patients?
    Lancet. 2023;402:751-753.
    PubMed    
    
    
    
41. MANSFIELD BS, Raal FJ
    Regression of cutaneous xanthomata in patient with homozygous familial hypercholesterolemia using novel therapies.
    Lancet. 2023;402:e11.
    PubMed    
    
    
    August 2023
42. RUGO HS, Bardia A, Marme F, Cortes J, et al
    Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Aug 23:S0140-6736(23)01245-X. doi: 10.1016/S0140-6736(23)01245.
    PubMed     Abstract available
    
    
    
43. THORNTON J
    Scabies in Cox's Bazar.
    Lancet. 2023;402:600.
    PubMed    
    
    
    July 2023
44. LONG GV, Swetter SM, Menzies AM, Gershenwald JE, et al
    Cutaneous melanoma.
    Lancet. 2023 Jul 24:S0140-6736(23)00821-8. doi: 10.1016/S0140-6736(23)00821.
    PubMed     Abstract available
    
    
    June 2023
45. COLES CE, Haviland JS, Kirby AM, Griffin CL, et al
    Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.
    Lancet. 2023 Jun 8:S0140-6736(23)00619-0. doi: 10.1016/S0140-6736(23)00619.
    PubMed     Abstract available
    
    
    April 2023
46. IQBAL M, Kharfan-Dabaja MA
    Cogent data on allogeneic haematopoietic stem-cell transplantation efficacy in advanced cutaneous T-cell lymphoma.
    Lancet. 2023 Apr 24:S0140-6736(23)00631-1. doi: 10.1016/S0140-6736(23)00631.
    PubMed    
    
    
    
47. DE MASSON A, Beylot-Barry M, Ram-Wolff C, Mear JB, et al
    Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
    Lancet. 2023 Apr 24:S0140-6736(23)00329-X. doi: 10.1016/S0140-6736(23)00329.
    PubMed     Abstract available
    
    
    
48. HAKIMI M, North JP, Taylor MA, Hailer A, et al
    Transcriptomics aids differentiation of IL-23 overactivity in a patient with atypical skin and joint disease.
    Lancet. 2023;401:1381.
    PubMed    
    
    
    
49. ANDRE F, Hee Park Y, Kim SB, Takano T, et al
    Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Apr 19:S0140-6736(23)00725-0. doi: 10.1016/S0140-6736(23)00725.
    PubMed     Abstract available
    
    
    
50. CHUMSRI S
    Advancing outcomes of metastatic HER2-positive breast cancer.
    Lancet. 2023 Apr 19:S0140-6736(23)00805-X. doi: 10.1016/S0140-6736(23)00805.
    PubMed    
    
    
    
51. 
    Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
    Lancet. 2023;401:1277-1292.
    PubMed     Abstract available
    
    
    
52. SHEN SJ, Liu CM
    Chemotherapy for early-stage breast cancer: the more the better?
    Lancet. 2023;401:1243-1245.
    PubMed    
    
    
    
53. MULLER M, Ingold-Heppner B, Stocker H, Heppner FL, et al
    Skin lesion specimens as first choice to detect monkeypox virus - Authors' reply.
    Lancet. 2023;401:1265.
    PubMed    
    
    
    
54. ZHOU YB
    Skin lesion specimens as first choice to detect monkeypox virus.
    Lancet. 2023;401:1264-1265.
    PubMed    
    
    
    
55. KING B, Zhang X, Harcha WG, Szepietowski JC, et al
    Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
    Lancet. 2023 Apr 13:S0140-6736(23)00222-2. doi: 10.1016/S0140-6736(23)00222.
    PubMed     Abstract available
    
    
    
56. JAVAUD N, Gobert D
    Hereditary angioedema: is there a better future for treatment?
    Lancet. 2023;401:1054-1055.
    PubMed    
    
    
    
57. CRAIG TJ, Reshef A, Li HH, Jacobs JS, et al
    Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2023;401:1079-1090.
    PubMed     Abstract available
    
    
    March 2023
58. EGEBERG A, Thyssen JP
    The optimal biologic treatment target for hidradenitis suppurativa remains undiscovered.
    Lancet. 2023;401:708-710.
    PubMed    
    
    
    
59. KIMBALL AB, Jemec GBE, Alavi A, Reguiai Z, et al
    Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
    Lancet. 2023;401:747-761.
    PubMed     Abstract available
    
    
    February 2023
60. CORREA-SELM L, Hanlon KL, Grichnik JM
    Differentiating activated Langerhans cells and dendritic melanocytes using reflectance confocal microscopy: the limitations of diagnosing melanoma in vivo.
    Lancet. 2023;401:590.
    PubMed    
    
    
    
61. AYGOREN-PURSUN E, Zanichelli A, Cohn DM, Cancian M, et al
    An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
    Lancet. 2023;401:458-469.
    PubMed     Abstract available
    
    
    
62. RESHEF A, Grumach AS
    New medications to mitigate attacks of hereditary angioedema: does one size fit all?
    Lancet. 2023;401:413-415.
    PubMed    
    
    
    January 2023
63. VOLKMANN ER, Andreasson K, Smith V
    Systemic sclerosis.
    Lancet. 2023;401:304-318.
    PubMed     Abstract available
    
    
    
64. ZHOU YB
    Pseudovesicular appearance in Sweet's syndrome: important yet easily missed.
    Lancet. 2023;401:104.
    PubMed    
    
    
    
65. BANARES J, Aceituno L, Jimenez A, Maynard A, et al
    Pseudovesicular appearance in Sweet's syndrome: important yet easily missed - Authors' reply.
    Lancet. 2023;401:104.
    PubMed    
    
    
    
66. CHUA BH, Link EK, Kunkler IH, Olivotto IA, et al
    Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost? - Authors' reply.
    Lancet. 2023;401:24.
    PubMed    
    
    
    
67. MULLIEZ T, De Ridder M
    Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost?
    Lancet. 2023;401:23-24.
    PubMed    
    
    
    
68. MEROLA JF, Landewe R, McInnes IB, Mease PJ, et al
    Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-alpha inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
    Lancet. 2023;401:38-48.
    PubMed     Abstract available
    
    
    
69. QUEIRO R
    Bimekizumab in psoriatic arthritis: a great leap forward?
    Lancet. 2023;401:2-3.
    PubMed    
    
    
    
70. MCINNES IB, Asahina A, Coates LC, Landewe R, et al
    Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
    Lancet. 2023;401:25-37.
    PubMed     Abstract available
    
    
    
71. MITJA O, Ogoina D, Titanji BK, Galvan C, et al
    Monkeypox.
    Lancet. 2023;401:60-74.
    PubMed     Abstract available
    
    
    December 2022
72. THYSSEN JP, Schmid-Grendelmeier P
    Long-term disease control in atopic dermatitis using biologics.
    Lancet. 2022 Dec 9:S0140-6736(22)02347-9. doi: 10.1016/S0140-6736(22)02347.
    PubMed    
    
    
    
73. GUTTMAN-YASSKY E, Simpson EL, Reich K, Kabashima K, et al
    An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.
    Lancet. 2022 Dec 9:S0140-6736(22)02037-2. doi: 10.1016/S0140-6736(22)02037.
    PubMed     Abstract available
    
    
    
74. RASSY E, Delaloge S
    A second-generation antibody-drug conjugate to treat HER2-positive breast cancer.
    Lancet. 2022 Dec 7:S0140-6736(22)02534-X. doi: 10.1016/S0140-6736(22)02534.
    PubMed    
    
    
    
75. HURVITZ SA, Hegg R, Chung WP, Im SA, et al
    Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
    Lancet. 2022 Dec 6:S0140-6736(22)02420-5. doi: 10.1016/S0140-6736(22)02420.
    PubMed     Abstract available
    
    
    November 2022
76. SANCHEZ-MEZA E, Kubelis-Lopez DE, Ocampo-Candiani J, Chavez-Alvarez S, et al
    Prominent skin folds of the scalp provide a superficial clue in acromegaly.
    Lancet. 2022;400:1802.
    PubMed    
    
    
    
77. VRSELJA A, Latifi A, Baber RJ, Stuckey BGA, et al
    Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial.
    Lancet. 2022;400:1704-1711.
    PubMed     Abstract available
    
    
    
78. CRANDALL CJ, Ganz PA
    Phase 2 data on a new treatment for hot flushes in women with breast cancer.
    Lancet. 2022;400:1659-1661.
    PubMed    
    
    
    October 2022
79. 
    Aqueous skin antisepsis before surgical fixation of open fractures (Aqueous-PREP): a multiple-period, cluster-randomised, crossover trial.
    Lancet. 2022;400:1334-1344.
    PubMed     Abstract available
    
    
    September 2022
80. KIM S, Wuthrick E, Blakaj D, Eroglu Z, et al
    Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
    Lancet. 2022;400:1008-1019.
    PubMed     Abstract available
    
    
    
81. SAIAG P, Blom A
    Combined nivolumab and ipilimumab in non-resectable Merkel cell carcinoma.
    Lancet. 2022;400:976-977.
    PubMed    
    
    
    
82. PALLER AS, Simpson EL, Siegfried EC, Cork MJ, et al
    Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2022;400:908-919.
    PubMed     Abstract available
    
    
    
83. HALLING AS, Thyssen JP
    Biological therapy for young children with atopic dermatitis.
    Lancet. 2022;400:867-869.
    PubMed    
    
    
    
84. LIVINGSTONE E, Zimmer L, Hassel JC, Fluck M, et al
    Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
    Lancet. 2022 Sep 9. pii: S0140-6736(22)01654.
    PubMed     Abstract available
    
    
    
85. SMITHY JW, Postow MA
    Adjuvant checkpoint blockade following complete local therapy for melanoma metastases.
    Lancet. 2022 Sep 9. pii: S0140-6736(22)01748.
    PubMed    
    
    
    August 2022
86. DESCAMPS V
    DRESS syndrome.
    Lancet. 2022;400:560.
    PubMed    
    
    
    
87. HINDIE E
    Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed?
    Lancet. 2022;400:559.
    PubMed    
    
    
    
88. LUKE JJ, Ibrahim N, Eggermont AM
    Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed? - Authors' reply.
    Lancet. 2022;400:559-560.
    PubMed    
    
    
    
89. CHUA BH, Link EK, Kunkler IH, Whelan TJ, et al
    Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.
    Lancet. 2022;400:431-440.
    PubMed     Abstract available
    
    
    
90. COLES CE, Chatterjee S, Jagsi R, Kirby AM, et al
    Breast radiotherapy for ductal carcinoma in situ: could less be more?
    Lancet. 2022;400:408-410.
    PubMed    
    
    
    July 2022
91. REICH K, Thyssen JP, Blauvelt A, Eyerich K, et al
    Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
    Lancet. 2022;400:273-282.
    PubMed     Abstract available
    
    
    
92. MENNINI M, Di Nardo G, Fiocchi AG
    Atopic dermatitis: time for tailored therapy.
    Lancet. 2022;400:252-253.
    PubMed    
    
    
    
93. RUDD EC, Kulasekararaj A, Basu TN
    Facial lymphoedema, viral warts, and myelodysplastic syndrome: the protean condition of GATA2 deficiency.
    Lancet. 2022;400:236.
    PubMed    
    
    
    June 2022
94. SKJERVEN HO, Lie A, Vettukattil R, Rehbinder EM, et al
    Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial.
    Lancet. 2022;399:2398-2411.
    PubMed     Abstract available
    
    
    
95. BANARES J, Aceituno L, Jimenez A, Maynard A, et al
    Sweet's syndrome and Crohn's disease diagnosed simultaneously.
    Lancet. 2022;399:2155.
    PubMed    
    
    
    May 2022
96. HIBI T
    Risankizumab for Crohn's disease.
    Lancet. 2022;399:1992-1993.
    PubMed    
    
    
    
97. DANESE S, Vermeire S, Zhou W, Pangan AL, et al
    Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Lancet. 2022 May 26. pii: S0140-6736(22)00581.
    PubMed     Abstract available
    
    
    
98. ABDELNABI M, Elmssary M, Sekhon J, Benjanuwattra J, et al
    Acute onset of fever, eosinophilia, rash, acute kidney injury, and a positive Monospot test in a patient on lamotrigine: DRESS syndrome.
    Lancet. 2022;399:1902.
    PubMed    
    
    
    April 2022
99. MEGALY M, Boshra N
    Pyogenic granuloma-like Kaposi's sarcoma.
    Lancet. 2022;399:e38.
    PubMed    
    
    
    
100. TCHERNEV G, Chokoeva AA
     Melanoma in a Chinese dragon tattoo.
     Lancet. 2022;399:e37.
     PubMed    
     
     
     March 2022
101. LUKE JJ, Rutkowski P, Queirolo P, Del Vecchio M, et al
     Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
     Lancet. 2022 Mar 31. pii: S0140-6736(22)00562.
     PubMed     Abstract available
     
     
     
102. DRIVENES JL, Betz RC, Bygum A
     A girl with unruly locks: molecular genetics makes a diagnosis of uncombable hair syndrome.
     Lancet. 2022;399:1079.
     PubMed    
     
     
     
103. CRAIG T, Magerl M, Levy DS, Reshef A, et al
     Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
     Lancet. 2022;399:945-955.
     PubMed     Abstract available
     
     
     
104. FIJEN LM, Levi M
     Prophylaxis with anti-activated factor XII for hereditary angioedema.
     Lancet. 2022;399:889-890.
     PubMed    
     
     
     February 2022
105. KUMAR A, Preston N, Phillips R
     Picturing health: Buruli ulcer in Ghana.
     Lancet. 2022;399:786-797.
     PubMed    
     
     
     
106. COLES CE, Anderson BO, Cameron D, Cardoso F, et al
     The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge.
     Lancet. 2022 Feb 18. pii: S0140-6736(22)00184.
     PubMed    
     
     
     December 2021
107. AL-MATAR SH, Sairam C, Roussel L, Langelier MJ, et al
     Fever, abdominal pain, serositis, arthralgia, hearing loss, proteinuria, and a family history: Muckle Wells syndrome.
     Lancet. 2021;398:2101.
     PubMed    
     
     
     November 2021
108. MURPHY MJ, Damsky W, Vesely MD
     A pruritic psoriatic plaque develops at the donor site of an autologous skin graft: Koebner phenomenon.
     Lancet. 2021;398:1836.
     PubMed    
     
     
     October 2021
109. GONZALES E, Hardikar W, Stormon M, Baker A, et al
     Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
     Lancet. 2021;398:1581-1592.
     PubMed     Abstract available
     
     
     April 2021
110. LOIBL S, Poortmans P, Morrow M, Denkert C, et al
     Breast cancer.
     Lancet. 2021 Apr 1. pii: S0140-6736(20)32381.
     PubMed     Abstract available
     
     
     March 2021
111. WANG C, Li A, Shi Q, Yu Z, et al
     Metagenomic next-generation sequencing clinches diagnosis of leishmaniasis.
     Lancet. 2021;397:1213.
     PubMed    
     
     
     January 2021
112. 
     Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries.
     Lancet. 2021;397:387-397.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Dermatology is free of charge.